Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.

Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.

Hyperfine, which markets the first US FDA-cleared portable MRI system, is facing COVID-related headwinds in bringing its system to hospitals, but CEO Dave Scott says wider adoption of the disruptive solution is inevitable. The company is going public today after combining with the HealthCor Catalio Acquisition Corp.

Under tax reform legislation recently passed by Congress, a 20% tax on products made in domestic territories will adversely affect the many device firms with Puerto Rican plants that currently enjoy a lower, 4% tax rate on profits. And a second tax provision usually relied upon by medtech companies, the R&D tax credit, also loses ground under the final Senate bill passed Dec. 2.